Trial Profile

Exenatide vs glimepiride in type 2 diabetic patients with insulin resistance

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Dec 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Exenatide (Primary) ; Glimepiride (Primary) ; Metformin
Indications Insulin resistance; Type 2 diabetes mellitus
Focus Therapeutic Use

Most Recent Events

08 Dec 2011 Results presented at the 21st World Diabetes Congress.
28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
05 Nov 2010 New trial record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com